Daiichi Sankyo Company ($DSKYF) announced an update on their ongoing clinical study. Daiichi Sankyo and Merck Launch New Lung Cancer Study With ...

If you are wondering whether Daiichi Sankyo Company is starting to look like a bargain or still has room to fall, you are not alone; this stock has quietly shifted from market favorite to value ...

The FDA placed the hold after researchers recorded a “higher than anticipated” incidence of deaths in a study testing “I-DXd” ...

Japanese pharmaceutical company Daiichi Sankyo plans to invest approximately 300 billion yen ($1.9 billion) to establish production facilities for targeted cancer ...

Fatima Attarwala is a business news writer and editor with a decade of experience researching, analyzing, and commenting on issues influencing the economy. Bloomberg / Contributor / Getty Images Merck ...

As Daiichi Sankyo and AstraZeneca’s metastatic breast cancer drug Enhertu picks up more label expansions, the companies are targeting patients directly for the first time in messaging efforts. Daiichi ...

Masahiro Kato takes over as Managing Director, Oliver Appelhans appointed to Head of the European Specialty Business Unit MUNICH--(BUSINESS WIRE)--Today, Daiichi Sankyo Europe GmbH, the European ...

Every year, April brings the peak bloom period for cherry blossom trees — and one pharma company is tying its involvement with the springtime ritual to its efforts in the oncology space. Japanese ...

Hiroyuki Okuzawa will step into the role starting in April. Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sunao Manabe, DVM, ...

Springtime in Washington, D.C., is synonymous with cherry blossom season, when the thousands of cherry blossom trees gifted to the city by Japan in the early 20th century show off their pink petals.

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr.